Growth hormone in pediatric chronic kidney disease: more than just height.
Recombinant human growth hormone therapy, which was introduced in the 1980s, is now routine for children with advanced chronic kidney disease (CKD) who are exhibiting growth impairment. Growth hormone usage remains variable across different centers, with some showing low uptake. Much of the focus on...
| Publicado en: | Pediatric Nephrology Vol. 39; no. 11; pp. 3167 - 3176 |
|---|---|
| Autores principales: | , |
| Formato: | algorithm pictorial review tables/charts Journal Article |
| Publicado: |
Springer Nature
Nov2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=179739454&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 179739454 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0931041X EF1 jtl: Pediatric Nephrology issn: 0931041X maglogo: N pubinfo: dt: Nov2024 vid: 39 iid: 11 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 179739454 176529068 179739454 179739454 10.1007/s00467-024-06330-8 179739454 ppf: 3167 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Growth hormone in pediatric chronic kidney disease: more than just height. aug: au: Sullivan, Katie Marie Kriegel, Alison J. affil: https://ror.org/00qqv6244 Division of Nephrology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA sug: subj: Human Growth Hormone Therapeutic Use Renal Insufficiency, Chronic Drug Therapy Growth Disorders Drug Therapy Body Height Psychosocial Factors Hormone Therapy Methods Pediatric Care Body Height Drug Effects Child Dietary Supplements Social Factors Child Development Growth In Infancy and Childhood Health Knowledge Cardiovascular Diseases Mortality Body Composition Bone and Bones Immunity Immune System Kidney Transplantation Nervous System Obesity Child: 6-12 years ab: Recombinant human growth hormone therapy, which was introduced in the 1980s, is now routine for children with advanced chronic kidney disease (CKD) who are exhibiting growth impairment. Growth hormone usage remains variable across different centers, with some showing low uptake. Much of the focus on growth hormone supplementation has been on increasing height because of social and psychological effects of short stature. There are, however, numerous other changes that occur in CKD that have not received as much attention but are biologically important for pediatric growth and development. This article reviews the current knowledge about the multisystem effects of growth hormone therapy in pediatric patients with CKD and highlights areas where additional clinical research is needed. We also included clinical data on children and adults who had received growth hormone for other indications apart from CKD. Ultimately, having robust clinical studies which examine these effects will allow children and their families to make more informed decisions about this therapy. pubtype: Academic Journal doctype: algorithm pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|